EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway

<div>Characterization of Ptoxin. (a) SDS-PAGE analysis of Ptoxin. Lane 1: Ptoxin; M: protein marker. (b) ELISA analysis of Ptoxin-binding potency for recombinant EGFR antigen. EC50 for Ptoxin is 0.4304 <i>μ</i>g/mL (95% confidence interval (CI): 0.3571-0.5189 <i>μ</i>g/mL). IgG was used as control. Points: mean of 3 independent determinations; bars: SD.</div>

Journal of Immunology Research

fig1

Figure 1

Figure 1: EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway 

Figure 1 | EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway 